Found: 893
Select item for more details and to access through your institution.
Nivolumab Efficacy and Safety in Cancer Patients with Renal Dysfunction.
- Published in:
- Medical Bulletin of Haseki / Haseki Tip Bulteni, 2024, v. 62, n. 4, p. 229, doi. 10.4274/haseki.galenos.2024.9916
- By:
- Publication type:
- Article
Model‐based population pharmacokinetic and exposure response analyses for safety and efficacy of nivolumab as adjuvant treatment in subjects with resected oesophageal or gastroesophageal junction cancer.
- Published in:
- British Journal of Clinical Pharmacology, 2024, v. 90, n. 11, p. 2920, doi. 10.1111/bcp.16188
- By:
- Publication type:
- Article
Relationship of Immune-Related Adverse Events with Tumor Response and Prognosis in Esophageal Squamous Cell Carcinoma Following Nivolumab Monotherapy.
- Published in:
- Cancers, 2024, v. 16, n. 20, p. 3529, doi. 10.3390/cancers16203529
- By:
- Publication type:
- Article
Hyperprogression after nivolumab for the treatment of melanoma.
- Published in:
- Indian Journal of Dermatology, Venereology & Leprology, 2023, v. 89, n. 4, p. 616, doi. 10.25259/IJDVL_160_2021
- By:
- Publication type:
- Article
Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies: a multicenter retrospective study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3065, doi. 10.1007/s00432-022-04206-8
- By:
- Publication type:
- Article
Non-specific symptoms as a prodrome of immune-related adverse events in patients with non-small cell lung cancer receiving nivolumab: a consecutive analysis of 200 patients.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3185, doi. 10.1007/s00432-022-04205-9
- By:
- Publication type:
- Article
Real world data on IO-based therapy for metastatic renal cell carcinoma.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2023, v. 149, n. 7, p. 3249, doi. 10.1007/s00432-022-04173-0
- By:
- Publication type:
- Article
The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2022, v. 148, n. 12, p. 3537, doi. 10.1007/s00432-022-04055-5
- By:
- Publication type:
- Article
Immune-related adverse events and immune checkpoint inhibitor tolerance on rechallenge in patients with irAEs: a single-center experience.
- Published in:
- Journal of Cancer Research & Clinical Oncology, 2021, v. 147, n. 9, p. 2789, doi. 10.1007/s00432-021-03610-w
- By:
- Publication type:
- Article
Chemokine level predicts the therapeutic effect of anti-PD-1 antibody (nivolumab) therapy for malignant melanoma.
- Published in:
- Archives of Dermatological Research, 2022, v. 314, n. 9, p. 887, doi. 10.1007/s00403-021-02305-z
- By:
- Publication type:
- Article
Use of Cystatin C to Assess Immunotherapy Toxicity in a Patient With Melanoma.
- Published in:
- Journal of Pharmacy Practice, 2022, v. 35, n. 2, p. 308, doi. 10.1177/0897190020966201
- By:
- Publication type:
- Article
The Role of the Pharmacist in Optimizing Cancer Immunotherapy: A Retrospective Study of Nivolumab Adverse Events.
- Published in:
- Journal of Pharmacy Practice, 2021, v. 34, n. 3, p. 386, doi. 10.1177/0897190019872937
- By:
- Publication type:
- Article
The Role of Immune-Inflammation Biomarkers to Predict the Response of Nivolumab in Second Line Treatment of Advanced Stage Non-Small Cell Lung Cancer.
- Published in:
- Eurasian Journal of Medical Investigation, 2024, v. 8, n. 1, p. 58, doi. 10.14744/ejmi.2023.36214
- By:
- Publication type:
- Article
Rechallenge Immunotherapy in Former Interferon-Treated Patients with Metastatic Renal Cell Carcinoma.
- Published in:
- Eurasian Journal of Medical Investigation, 2024, v. 8, n. 1, p. 43, doi. 10.14744/ejmi.2023.11907
- By:
- Publication type:
- Article
Combined LDH Albumin Score (CLAS) and Neutrophil-Lymphocyte Ratio (NLR) are Predictive for Survival in Patients with Metastatic Non-Small Cell Carcinoma Treated with Nivolumab as Monotherapy.
- Published in:
- Eurasian Journal of Medical Investigation, 2024, v. 8, n. 1, p. 28, doi. 10.14744/ejmi.2023.21564
- By:
- Publication type:
- Article
Prognostic Effect of Psoas Muscle Index, a Parameter of Sarcopenia, in Solid Cancer Patients Receiving Immunotherapy.
- Published in:
- Eurasian Journal of Medical Investigation, 2023, v. 7, n. 4, p. 361, doi. 10.14744/ejmi.2023.30675
- By:
- Publication type:
- Article
Evaluation of Immunotherapy and Targeted Therapies in the Treatment of Metastatic Malignant Melanoma.
- Published in:
- Eurasian Journal of Medical Investigation, 2022, v. 6, n. 4, p. 429, doi. 10.14744/ejmi.2022.79013
- By:
- Publication type:
- Article
Opdivo Now Approved for Adjuvant Treatment of Stage IIB/C Melanoma.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 6, p. 14
- Publication type:
- Article
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC.
- Published in:
- Value-Based Cancer Care, 2023, v. 14, n. 6, p. 1
- By:
- Publication type:
- Article
Novel LAG-3-Blocking Antibody plus Nivolumab Shows Promise as First-Line Treatment in Advanced Melanoma.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 4, p. 9
- By:
- Publication type:
- Article
Early Phase 3 Results Show Survival Benefit with Nivolumab-Based Regimens in Advanced Esophageal Squamous-Cell Cancer.
- Published in:
- Value-Based Cancer Care, 2021, v. 12, n. 4, p. 11
- By:
- Publication type:
- Article
SC Nivolumab Could Reduce Disparities in the Care of Patients With Clear Cell Renal Cell Carcinoma.
- Published in:
- Oncology Practice Management, 2024, v. 14, n. 4, p. 18
- Publication type:
- Article
Perioperative Nivolumab Extends Event-Free Survival in Resectable NSCLC.
- Published in:
- Oncology Practice Management, 2023, v. 13, n. 12, p. 1
- By:
- Publication type:
- Article
First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 30
- Publication type:
- Article
Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma.
- Published in:
- Oncology Practice Management, 2022, v. 12, n. 5, p. 16
- By:
- Publication type:
- Article
Pilot Study Shows Clinical Benefit with Nivolumab in Pediatric Patients with Hypermutant Cancers.
- Published in:
- Oncology Practice Management, 2021, v. 11, n. 12, p. 30
- By:
- Publication type:
- Article
Neoadjuvant Nivolumab plus Chemotherapy Significantly Improves Pathologic Complete Response in Patients with Resectable NSCLC.
- Published in:
- Oncology Practice Management, 2021, v. 11, n. 9, p. 17
- By:
- Publication type:
- Article
Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma.
- Published in:
- Oncology Practice Management, 2021, v. 11, n. 10, p. 37
- Publication type:
- Article
Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta‐analysis.
- Published in:
- Journal of Cosmetic Dermatology, 2024, v. 23, n. 4, p. 1165, doi. 10.1111/jocd.16105
- By:
- Publication type:
- Article
Nivolumab‐induced plaque morphea in a malign melanoma patient.
- Published in:
- Journal of Cosmetic Dermatology, 2021, v. 20, n. 8, p. 2645, doi. 10.1111/jocd.13914
- By:
- Publication type:
- Article
Diabetes Mellitus Induced by Nivolumab plus Regorafenib in a Patient with Esophageal Cancer.
- Published in:
- Journal of Cancer Research & Practice, 2024, v. 11, n. 2, p. 81, doi. 10.4103/ejcrp.eJCRP-D-23-00025
- By:
- Publication type:
- Article
Multiple immunosuppressants for immune-related acholia in a patient with metastatic colorectal cancer.
- Published in:
- Journal of Cancer Research & Practice, 2023, v. 10, n. 1, p. 38, doi. 10.4103/ejcrp.eJCRP-D-22-00026
- By:
- Publication type:
- Article
Triad of myasthenia gravis, myositis, and myocarditis after nivolumab administration in a patient with cholangiocarcinoma.
- Published in:
- Journal of Cancer Research & Practice, 2022, v. 9, n. 4, p. 153, doi. 10.4103/2311-3006.362636
- By:
- Publication type:
- Article
Durable response of immune checkpoint inhibitor for a patient with advanced gastric adenosquamous carcinoma.
- Published in:
- Journal of Cancer Research & Practice, 2022, v. 9, n. 4, p. 145, doi. 10.4103/2311-3006.362634
- By:
- Publication type:
- Article
Myasthenia Gravis Lambert-Eaton overlap syndrome induced by nivolumab in a metastatic melanoma patient.
- Published in:
- Neurological Sciences, 2021, v. 42, n. 12, p. 5377, doi. 10.1007/s10072-021-05557-9
- By:
- Publication type:
- Article
Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma.
- Published in:
- Central European Journal of Immunology, 2023, v. 48, n. 3, p. 251, doi. 10.5114/ceji.2023.130864
- By:
- Publication type:
- Article
Nivolumab in two cases of refractory mycosis fungoides erythroderma.
- Published in:
- 2021
- By:
- Publication type:
- Case Study
Elevated serum lactate dehydrogenase to albumin ratio is a useful poor prognostic predictor of nivolumab in patients with non-small cell lung cancer.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2023, v. 27, p. 86
- By:
- Publication type:
- Article
Nivolumab as a bridge to allogeneic hematopoietic stem cell transplantation is associated with improved survival.
- Published in:
- European Review for Medical & Pharmacological Sciences, 2022, v. 26, n. 3, p. 957
- By:
- Publication type:
- Article
Giant cell arteritis and therapeutic response: a dual facet of immunotherapy in metastatic clear cell renal carcinoma.
- Published in:
- Oxford Medical Case Reports, 2024, v. 2024, n. 7, p. 1, doi. 10.1093/omcr/omae082
- By:
- Publication type:
- Article
P8‐172: A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 355, doi. 10.1111/resp.14150_684
- Publication type:
- Article
P8‐144: Prognostic value of neutrophil‐to‐lymphocyte ratio in patients of malignant pleural mesothelioma treated with nivolumab.
- Published in:
- Respirology, 2021, v. 26, p. 344, doi. 10.1111/resp.14150_656
- Publication type:
- Article
P8‐137: Association of immune‐related adverse events with therapeutic response to nivolumab in patients with malignant pleural mesothelioma.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_649
- Publication type:
- Article
P8‐136: Nivolumab for malignant mesothelioma: A real‐word experience.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_648
- Publication type:
- Article
P8‐119: An autopsy case of immune‐related severe colitis consequent to long‐term treatment with nivolumab in a patient with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 334, doi. 10.1111/resp.14150_631
- Publication type:
- Article
P8‐104: The clinical outcomes of nivolumab plus ipilimumab combined with platinum‐based chemotherapy, single‐center, retrospective analysis.
- Published in:
- Respirology, 2021, v. 26, p. 329, doi. 10.1111/resp.14150_616
- Publication type:
- Article
P8‐82: CD8‐positive peripheral T cell lymphoma in a patient following long‐term nivolumab for advanced lung adenocarcinoma: A case report.
- Published in:
- Respirology, 2021, v. 26, p. 319, doi. 10.1111/resp.14150_594
- Publication type:
- Article
P8‐34: The relation between immune‐related adverse events and therapeutic effects of nivolumab or pembrolizumab monotherapy for patients with non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 300, doi. 10.1111/resp.14150_546
- Publication type:
- Article
P8‐172: A retrospective study of the efficacy and safety of nivolumab plus ipilimumab combination therapy for advanced stage non‐small cell lung cancer.
- Published in:
- Respirology, 2021, v. 26, p. 355, doi. 10.1111/resp.14150_684
- Publication type:
- Article
P8‐137: Association of immune‐related adverse events with therapeutic response to nivolumab in patients with malignant pleural mesothelioma.
- Published in:
- Respirology, 2021, v. 26, p. 341, doi. 10.1111/resp.14150_649
- Publication type:
- Article